Australia markets closed

Fulgent Genetics, Inc. (FLGT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
21.50+0.26 (+1.22%)
At close: 04:00PM EDT
21.25 -0.25 (-1.16%)
After hours: 06:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close21.24
Open20.50
Bid21.48 x 400
Ask21.56 x 100
Day's range20.50 - 21.60
52-week range19.88 - 44.09
Volume353,971
Avg. volume217,050
Market cap643.372M
Beta (5Y monthly)1.42
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Fulgent Reports First Quarter 2024 Financial Results

    EL MONTE, Calif., May 03, 2024--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2024.

  • Business Wire

    Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024

    EL MONTE, Calif., April 11, 2024--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2024 financial results before the market opens on Friday, May 3, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions.

  • Business Wire

    Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results

    EL MONTE, Calif., February 28, 2024--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2023.